๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Recruitingn/aAges 18 Years - anyAllHunan Province Tumor Hospital
NCT04324164 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * 18๏ผŒAdvanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
๐Ÿ’Š

What it tests

  • Third-generation EGFR-TKI
  • EGFR-TKI
๐Ÿ“

Where

1 site
Yongchang Zhang
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy